Cytokinetics Shares Bought by Hudson Bay Capital

Institutional investor increases stake in biopharmaceutical company

Mar. 20, 2026 at 9:37am

Got story updates? Submit your updates here. ›

Hudson Bay Capital Management LP has increased its position in Cytokinetics, Incorporated (NASDAQ:CYTK) by 15.4% during the 3rd quarter, according to a recent SEC filing. The institutional investor now owns 182,131 shares of the biopharmaceutical company's stock, worth $10,010,000.

Why it matters

Cytokinetics is a late-stage biopharmaceutical company focused on developing novel small-molecule therapeutics that modulate muscle function. The increase in Hudson Bay Capital's stake suggests institutional confidence in the company's pipeline and future prospects.

The details

According to the filing, Hudson Bay Capital acquired an additional 24,345 shares of Cytokinetics during the 3rd quarter, bringing its total ownership to 0.15% of the company. The move comes as Cytokinetics has seen increased analyst coverage and price target raises in recent months, with Mizuho and JPMorgan both issuing bullish notes on the stock.

  • Hudson Bay Capital increased its Cytokinetics stake during the 3rd quarter of 2026.

The players

Hudson Bay Capital Management LP

An institutional investor and hedge fund that has increased its stake in Cytokinetics.

Cytokinetics, Incorporated

A late-stage biopharmaceutical company focused on developing novel small-molecule therapeutics that modulate muscle function.

Got photos? Submit your photos here. ›

The takeaway

The increased institutional investment in Cytokinetics by a fund like Hudson Bay Capital suggests growing confidence in the company's pipeline and future growth potential within the biopharmaceutical industry.